Mark T Muir1, Stephen M Cohn2, Christopher Louden3, Thirumalai R Kannan4, Joel B Baseman4. 1. Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio, TX. 2. Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio, TX. Electronic address: cohn@uthscsa.edu. 3. Department of Epidemiology and Biostatistics, University of Texas Health Science Center at San Antonio, San Antonio, TX. 4. Department of Microbiology and Immunology, University of Texas Health Science Center at San Antonio, San Antonio, TX.
Abstract
BACKGROUND: Community-acquired respiratory distress syndrome (CARDS) toxin is a unique Mycoplasma pneumoniae virulence factor. Molecular assays targeting this toxin are more sensitive than existing diagnostics, but these assays have not been used to investigate the role of M pneumoniae as a nosocomial infection in critical illness. We sought to determine the incidence of M pneumoniae among mechanically ventilated subjects using these novel assays and to investigate the impact of this pathogen on pulmonary outcomes. METHODS: We conducted a prospective observational study enrolling subjects with suspected ventilator-associated pneumonia (VAP) undergoing BAL in the surgical trauma ICU at a level I trauma center. Lavage fluid and serum samples were tested for M pneumoniae using assays to detect CARDS toxin gene sequences, protein, or antitoxin antibodies. RESULTS: We collected samples from 37 subjects, with 41% (15 of 37) testing positive using these assays. The positive and negative groups did not differ significantly in baseline demographic characteristics, including age, sex, injury severity, or number of ventilator days before bronchoscopy. The positive group had significantly fewer ventilator-free days (P = .04) and lower average oxygenation (P = .02). These differences were most pronounced among subjects with ARDS. CONCLUSIONS: Evidence is provided that M pneumoniae is present in a substantial number of subjects with suspected VAP. Subjects testing positive experience a significantly longer ventilator course and worse oxygenation compared with subjects testing negative.
BACKGROUND: Community-acquired respiratory distress syndrome (CARDS) toxin is a unique Mycoplasma pneumoniae virulence factor. Molecular assays targeting this toxin are more sensitive than existing diagnostics, but these assays have not been used to investigate the role of M pneumoniae as a nosocomial infection in critical illness. We sought to determine the incidence of M pneumoniae among mechanically ventilated subjects using these novel assays and to investigate the impact of this pathogen on pulmonary outcomes. METHODS: We conducted a prospective observational study enrolling subjects with suspected ventilator-associated pneumonia (VAP) undergoing BAL in the surgical trauma ICU at a level I trauma center. Lavage fluid and serum samples were tested for M pneumoniae using assays to detect CARDS toxin gene sequences, protein, or antitoxin antibodies. RESULTS: We collected samples from 37 subjects, with 41% (15 of 37) testing positive using these assays. The positive and negative groups did not differ significantly in baseline demographic characteristics, including age, sex, injury severity, or number of ventilator days before bronchoscopy. The positive group had significantly fewer ventilator-free days (P = .04) and lower average oxygenation (P = .02). These differences were most pronounced among subjects with ARDS. CONCLUSIONS: Evidence is provided that M pneumoniae is present in a substantial number of subjects with suspected VAP. Subjects testing positive experience a significantly longer ventilator course and worse oxygenation compared with subjects testing negative.
Authors: Jonas M Winchell; Kathleen A Thurman; Stephanie L Mitchell; W Lanier Thacker; Barry S Fields Journal: J Clin Microbiol Date: 2008-07-09 Impact factor: 5.948
Authors: J L Trouillet; J Chastre; A Vuagnat; M L Joly-Guillou; D Combaux; M C Dombret; C Gibert Journal: Am J Respir Crit Care Med Date: 1998-02 Impact factor: 21.405
Authors: Petra Apfalter; Brigitte Stoiser; Wolfgang Barousch; Marion Nehr; Ludwig Kramer; Heinz Burgmann Journal: Crit Care Med Date: 2005-07 Impact factor: 7.598
Authors: T R Kannan; R D Hardy; J J Coalson; D C Cavuoti; J D Siegel; M Cagle; O Musatovova; C Herrera; J B Baseman Journal: Clin Infect Dis Date: 2011-11-03 Impact factor: 9.079
Authors: Jorge L Medina; Jacqueline J Coalson; Edward G Brooks; Vicki T Winter; Adriana Chaparro; Molly F R Principe; Thirumalai R Kannan; Joel B Baseman; Peter H Dube Journal: Am J Respir Cell Mol Biol Date: 2012-01-26 Impact factor: 6.914
Authors: Jay Peters; Harjinder Singh; Edward G Brooks; Joseph Diaz; Thirumalai R Kannan; Jacqueline J Coalson; Janet G Baseman; Marianna Cagle; Joel B Baseman Journal: Chest Date: 2011-05-26 Impact factor: 9.410
Authors: Ryan M Huebinger; Ming-Mei Liu; Scot E Dowd; Fernando A Rivera-Chavez; John Boynton; Curtis Carey; Kenneth Hawkins; Christian T Minshall; Steven E Wolf; Joseph P Minei; Robert C Barber Journal: Surg Infect (Larchmt) Date: 2013-05-06 Impact factor: 2.150
Authors: Sowmya Balasubramanian; Lavanya Pandranki; Suzanna Maupin; Kumaraguruparan Ramasamy; Alexander B Taylor; Peter John Hart; Joel B Baseman; Thirumalai R Kannan Journal: Cell Microbiol Date: 2019-05-09 Impact factor: 3.715
Authors: Thirumalai R Kannan; Manickam Krishnan; Kumaraguruparan Ramasamy; Argentina Becker; Olga N Pakhomova; P John Hart; Joel B Baseman Journal: Mol Microbiol Date: 2014-07-10 Impact factor: 3.501
Authors: Kumaraguruparan Ramasamy; Sowmya Balasubramanian; Alejandra Kirkpatrick; Daniel Szabo; Lavanya Pandranki; Joel B Baseman; T R Kannan Journal: Sci Rep Date: 2021-06-02 Impact factor: 4.379